Sangamo Therapeutics Inc
$ 0.47
20.63%
24 Feb - close price
- Market Cap 175,621,000 USD
- Current Price $ 0.47
- High / Low $ 0.49 / 0.39
- Stock P/E N/A
- Book Value 0.02
- EPS -0.45
- Next Earning Report 2026-03-16
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.68 %
- ROE -4.80 %
- 52 Week High 1.06
- 52 Week Low 0.34
About
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic drugs that transform the lives of patients using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company is headquartered in Brisbane, California.
Analyst Target Price
$3.81
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-25 | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-03-11 | 2024-11-01 | 2024-08-06 | 2024-05-09 | 2024-03-13 | 2023-11-01 | 2023-08-08 | 2023-04-26 |
| Reported EPS | 0 | -0.11 | -0.08 | -0.14 | -0.11 | 0.0438 | -0.18 | -0.27 | -0.34 | -0.59 | -0.66 | 0.12 |
| Estimated EPS | -0.0277 | 0.0002 | -0.02 | -0.13 | -0.0909 | -0.03 | -0.15 | -0.21 | -0.26 | -0.32 | -0.34 | -0.33 |
| Surprise | 0.0277 | -0.1102 | -0.06 | -0.01 | -0.0191 | 0.0738 | -0.03 | -0.06 | -0.08 | -0.27 | -0.32 | 0.45 |
| Surprise Percentage | 100% | -55100% | -300% | -7.6923% | -21.0121% | 246% | -20% | -28.5714% | -30.7692% | -84.375% | -94.1176% | 136.3636% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-16 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.01 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SGMO
2026-02-21 11:24:40
Roche has licensed Sangamo Therapeutics' "zinc finger" technology to pursue new genomic medicines for neurodegenerative diseases, specifically targeting the tau protein implicated in Alzheimer's. The deal, valued at nearly $2 billion, includes $50 million upfront for Sangamo and potential additional payments, providing a much-needed cash injection for the biotech company, which has recently faced layoffs and pipeline cuts. Genentech, Roche's research arm, will lead clinical development and commercialization, while Sangamo handles initial preclinical activities.
2026-02-17 01:58:19
This article reports that the price target for Sangamo Therapeutics (SGMO) has been increased by 17.31%, bringing it to $3.89. The article is very short and provides only this specific piece of financial data.
2026-02-11 13:27:56
HC Wainwright analyst P. Trucchio has issued a FY2030 earnings per share (EPS) forecast of $0.67 for Sangamo Therapeutics (SGMO), maintaining a "Buy" rating and a $10 price target. This forecast contrasts with the current consensus full-year estimate of ($0.46) per share. Sangamo Therapeutics, a clinical-stage biotech focusing on gene-editing therapies, has active institutional ownership and trades significantly below the analyst's price target.
2026-02-09 17:33:04
Interim data from the Phase 1/2 STAAR clinical trial indicates that Sangamo Therapeutics' investigational gene therapy, ST-920 (isaralgagene civaparvovec), is well tolerated and shows promise in treating Fabry disease. The data reveals stabilized kidney function, reduced disease severity, and improved quality of life in adult patients after one year. Sangamo expects to complete dosing soon and is preparing for a Phase 3 trial, while also seeking partnerships and financing.
2026-02-05 15:28:47
Sangamo Therapeutics has initiated a rolling submission to the FDA for accelerated approval of its experimental gene therapy, isaralgagene civaparvovec, for Fabry disease. The therapy aims to deliver a healthy GLA gene to liver cells to produce a functional alpha-Gal A enzyme. New data from the Phase 1/2 STAAR trial indicates improved kidney function and stable heart health in patients treated with the gene therapy, with a favorable safety profile allowing some patients to discontinue enzyme replacement therapy.
2026-02-04 21:28:47
Sangamo Therapeutics recently announced promising Phase 1/2 STAAR study results for its Fabry disease gene therapy, isaralgagene civaparvovec, and confirmed a rolling Biologics License Application submission to the FDA via the Accelerated Approval pathway. This regulatory progress was coupled with a US$24.82 million equity raise and a change in finance leadership, highlighting both significant opportunities and ongoing funding challenges for the company's gene therapy. While the FDA's Accelerated Approval pathway for ST-920 offers a clearer near-term catalyst and upside narrative, the recent capital raise and historical losses underscore persistent funding and execution pressures for Sangamo.
